Valerio Therapeutics (XPAR:ALVIO) Total Equity: €2.08 Mil (As of Dec. 2025)


XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
28 GF Score
Price €0.51
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics Total Equity?

Valerio Therapeutics XPAR:ALVIO +37.84% 28 Total Equity is €2.08 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVIO with a GF Score™ of 28/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Valerio Therapeutics's total equity for the quarter that ended in Dec. 2025 was €2.08 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Valerio Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Valerio Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valerio Therapeutics Total Equity Chart

Valerio Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.94 22.27 14.81 -8.27 2.08

Valerio Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.81 4.02 -8.27 -8.45 2.08
XPAR:ALVIO
28GF Score
Valerio Therapeutics XPAR:ALVIO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valerio Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Valerio Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=15.234-13.159
=2.08

Valerio Therapeutics's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=15.234-13.159
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €2.08 Mil mean?
Valerio Therapeutics (XPAR:ALVIO) has a Total Equity of €2.08 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Valerio Therapeutics and its competitors.
Is Valerio Therapeutics' Total Equity too high?
Valerio Therapeutics' current Total Equity is €2.08 Mil. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Total Equity compare to VRTX and REGN?
Valerio Therapeutics' Total Equity of €2.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Valerio Therapeutics and its competitors. Valerio Therapeutics's current Total Equity is €2.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.51 — trading 628.6% above its estimated fair value. The current Total Equity is €2.08 Mil. Valerio Therapeutics' overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Total Equity is €2.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Total Equity: €2.08 Mil
  • GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
  • GF Score™: 28/100 with 9 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score

Get the complete analysis for XPAR:ALVIO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.07
GF Value